Method Development, Validation and Forced Degradation Studies of Dapagliflozin and Pioglitazone Hydrochlorides in Synthetic Mixtures by RP-HPLC [PDF]
, 2022 A simple, sensitive, robust, precise, and efficient RP-HPLC approach for the simultaneous determination of Dapagliflozin and Pioglitazone Hydrochloride in Synthetic Mixture.
Mr. Tarang, Patel, Ronak, Parikh
core
Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
Therapeutic Advances in Endocrinology and Metabolism, 2015 Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor approved as a treatment for type 2 diabetes mellitus (T2DM) in the United States, the European Union and other countries.
Deborah Hinnen
doaj +1 more source
Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice
Frontiers in Pharmacology, 2022 Nonalcoholic fatty liver disease (NAFLD), which is the most common liver disease, is associated with type 2 diabetes mellitus and metabolic syndrome. Although there is no consensus on the treatment of NAFLD, growing evidence suggests that tight glycemic ...
Panshuang Qiao +9 more
doaj +1 more source
An emerging protagonist: Sodium Glucose Co-transporters (SGLTs) as a burgeoning target for the treatment of diabetes mellitus [PDF]
, 2012 Contemporary therapies to rationalize the hyperglycaemia in type 2 diabetes mellitus (T2DM) generally involve insulin-dependent mechanisms and lose their effectiveness as pancreatic b-cell function decreases to a greater extent. The kidney emerges out as
Manju Sharma +4 more
core +1 more source
Effects of SGLT-2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine-N-Oxide in Patients With Type-2 Diabetes. [PDF]
Endocrinol Diabetes MetabTreatment with empagliflozin or dapagliflozin was associated with a modest increase in plasma concentration of TMAO in Type 2 diabetes patients. These findings suggest a possible class effect of SGLT‐2 inhibitors. Whether this effect impacts the overall clinical benefits of SGLT‐2 inhibitors needs to be subject to further investigation.
Zimmer KB +6 more
europepmc +2 more sources
Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea [PDF]
, 2018 INTRODUCTION: Sodium glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin, have demonstrated favorable effects in patients with type 2 diabetes (T2D).
이병완
core +1 more source
Dapagliflozin Saxagliptin Insulin Study
Simonson DC, Testa MA, Ekholm E, Su M, Vilsboll T, Jabbour S, Lind M. Continuous Glucose Monitoring Profiles and Health Outcomes after Dapagliflozin Plus Saxagliptin vs Insulin Glargine.
Donald Craig Simonson M.D.
core +8 more sources
Biomedicines, 2023 Cognitive decline and Alzheimer-like neuropathology are common manifestations of cadmium toxicity. Thanks to its antioxidant/anti-apoptotic features, dapagliflozin has demonstrated promising neuroprotective actions. However, its effect on cadmium-induced
Hany H. Arab +6 more
doaj +1 more source
Pharmacovigilance national survey of dapagliflozin in France
, 2023 International audienceIntroduction: Dapagliflozin is an inhibitor of the sodium-glucose co-transporter type 2 (SGLT2) indicated for the treatment of type 2 diabetes, and more recently for chronic heart failure with reduced ejection fraction, and chronic ...
Beyens, Marie-Noëlle, Faillie, Jean-Luc
core +4 more sources
Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo-controlled, double blind, cross-over pilot study. [PDF]
, 2018 We investigated the short-term effects of dapagliflozin as adjunct to insulin on insulin sensitivity, postprandial glucose excursions and ketone body production in type 1 diabetes mellitus (T1DM).
Ebenbichler, Christoph F +17 more
core +1 more source